Henry Schein, Inc. (HSIC) is the world's largest provider of healthcare solutions to office-based dental and medical practitioners. Headquartered in Melville, New York and founded in 1932, the company distributes dental and medical supplies, equipment, and technology through its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments.
After years of trading well below its peak, the stock has climbed back toward its record high. The shares' all-time high of roughly $92.68 was set in April 2022, and the stock currently trades in the upper $80s. For many investors, $100 has become the natural psychological milestone to watch: it sits above the prior peak, matches several fresh analyst price targets, and would confirm a decisive breakout into uncharted territory.
The stock has shown meaningful momentum over the past year, rallying from the low $60s toward the low $90s and bringing its 52-week range to approximately $61.95 to $92.18. With a market capitalization of roughly $10 billion and trailing twelve-month revenue near $13.6 billion, Henry Schein remains a sizable but relatively low-beta (around 0.8) healthcare distributor.
Fundamentally, the company has been improving. Its second-quarter 2026 results, reported in early August, featured strong sales, margin expansion, and double-digit earnings growth. Non-GAAP (non-GAAP measures exclude certain one-time items) earnings per share came in at $1.27 versus a consensus estimate near $1.24, on revenue of about $3.5 billion. Management also raised its full-year guidance for both revenue growth and non-GAAP earnings per share.
Several factors support a continued move toward $100. The company has been gaining share in its core dental and specialty segments, and its push into technology adoption and value-added services is expanding revenue beyond traditional product distribution. Margin improvement—driven by operating leverage and cost discipline—has been a recurring theme in recent earnings commentary.
The analyst community has responded positively. Following the quarterly report, multiple firms raised their price targets to $100 or above, including Barclays ($100), J.P. Morgan ($102), Barrington ($104), Baird ($109), BTIG ($110), and Citi ($112). The consensus rating remains a "Buy," and the average 12-month price target sits near $98. A continued cadence of estimate increases, coupled with stable demand from dental and medical practices, would strengthen the path toward the $100 threshold.
The path is not without risk. Despite the broadly positive consensus, a meaningful minority of analysts remain cautious. Morgan Stanley holds an Underweight-equivalent stance with a target near $64, while Mizuho and BMO Capital carry Hold-type ratings with targets in the mid-$80s—below the current price. This dispersion reflects genuine debate over valuation and the durability of recent momentum.
Execution risk is also a live concern. The company recently announced leadership transitions, including the departure of several senior executives and the creation of a new leadership team, and some analysts have noted that a newer chief executive has yet to fully establish investor credibility. On valuation, the stock trades at a trailing price-to-earnings ratio in the mid-20s—above its historical median—meaning a miss on guidance or a slowdown in dental demand could pressure the shares quickly.
From a technical analysis standpoint, $100 is both a psychological resistance level and a record-high threshold. Before that, the stock must clear its prior all-time high around $92.68, which also aligns with the upper end of the 52-week range. A sustained move above that zone would mark a breakout from a long-term base.
On the downside, the low-to-mid $80s represent a nearby support area where the stock consolidated after its rally, while the 52-week low near $62 provides a much deeper floor. As long as the shares hold above the $80s, the longer-term uptrend structure remains intact.
The consensus analyst price target is approximately $98, with a high of $112 and a low of $64. This places the $100 objective comfortably within—but slightly above—the consensus view. In other words, $100 is not an outlandish stretch; it is a level several prominent firms explicitly endorse, while a handful of skeptics argue the stock is already fully valued.
Traders seeking a more systematic read on Henry Schein and thousands of other stocks and ETFs can turn to Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor changing market conditions and generate Buy, Sell, or Hold signals based on technical behavior and AI-driven analysis. By scanning for shifts in momentum and trend, the product aims to help traders spot emerging opportunities, track existing positions, and identify changing market trends more efficiently than manual chart review. Investors watching whether HSIC can clear its record highs may find these daily signals a useful complement to fundamental research.
A move to $100 for Henry Schein is realistic but not guaranteed. The company's improved earnings, raised guidance, and a series of analyst target increases above $100 provide a credible foundation, and the level itself is a natural psychological milestone that several firms already endorse. The primary risks are valuation, executive turnover, and the lingering group of analysts who see the stock as fully priced.
What would likely be required is continued evidence of margin expansion and market-share gains over the next several quarters, ideally accompanied by the shares decisively clearing their prior all-time high near $92–93. Investors should monitor guidance updates, leadership stability, and whether the stock can hold support in the low-to-mid $80s during any pullback.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that HSIC and CAH have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HSIC and CAH's prices will move in lockstep.
| Ticker / NAME | Correlation To HSIC | 1D Price Change % | ||
|---|---|---|---|---|
| HSIC | 100% | +0.52% | ||
| CAH - HSIC | 28% Poorly correlated | +1.27% | ||
| MCK - HSIC | 26% Poorly correlated | -0.37% | ||
| COR - HSIC | 23% Poorly correlated | +0.26% | ||
| YI - HSIC | 7% Poorly correlated | +0.29% | ||
| ACH - HSIC | 6% Poorly correlated | +4.27% | ||
More | ||||